Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?

Lignende værker

• COVID-19, acute respiratory distress syndrome (ARDS), and hyperbaric oxygen therapy (HBOT): what is the link?
  af: De Maio, Antonio, et al.
  Udgivet: (2020)
• How Could This Happen?: Narrowing Down the Contagion of COVID-19 and Preventing Acute Respiratory Distress Syndrome (ARDS)
  af: Allaerts, Wilfried
  Udgivet: (2020)
• Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis
  af: Caocci, Giovanni, et al.
  Udgivet: (2021)
• COVID‐19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre‐COVID‐19 ARDS
  af: Gibson, Peter G, et al.
  Udgivet: (2020)
• Acute Respiratory Distress Syndrome (ARDS)
  Udgivet: (2024)